590 related articles for article (PubMed ID: 24044798)
1. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
[TBL] [Abstract][Full Text] [Related]
2. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
[TBL] [Abstract][Full Text] [Related]
3. Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.
de Glas NA; Fontein DB; Bastiaannet E; Pijpe A; De Craen AJ; Liefers GJ; Nortier HJ; de Haes HJ; van de Velde CJ; van Leeuwen FE
Cancer; 2014 Sep; 120(18):2847-54. PubMed ID: 24840230
[TBL] [Abstract][Full Text] [Related]
4. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
5. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
[TBL] [Abstract][Full Text] [Related]
8. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
9. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
Buzdar AU
Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
[TBL] [Abstract][Full Text] [Related]
12. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
[TBL] [Abstract][Full Text] [Related]
14. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
15. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
[TBL] [Abstract][Full Text] [Related]
16. [Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results].
Fodor J; Mózsa E; Zaka Z; Polgár C; Major T
Magy Onkol; 2005; 49(3):203, 205-8. PubMed ID: 16249814
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
Abdulkarim BS; Cuartero J; Hanson J; Deschênes J; Lesniak D; Sabri S
J Clin Oncol; 2011 Jul; 29(21):2852-8. PubMed ID: 21670451
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
19. Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.
Min SY; Lee SJ; Shin KH; Park IH; Jung SY; Lee KS; Ro J; Lee S; Kim SW; Kim TH; Kang HS; Cho KH
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e697-705. PubMed ID: 21129858
[TBL] [Abstract][Full Text] [Related]
20. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection.
Lupe K; Truong PT; Alexander C; Speers C; Tyldesley S
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e681-8. PubMed ID: 21300456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
